The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 386-393

  Andresen, Silke ^a   Brandt, Juliane ^a   Dietrich, Sascha ^a   Memmer, Marie Luise ^a   Ho, Anthony D ^a   Witzens Harig, Mathias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

High dose therapy; Lymphoma; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANOREXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVOR; COGNITION; CONSTIPATION; DIARRHEA; DRUG MEGADOSE; DYSPNEA; EMOTIONALITY; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; FUNCTIONAL ASSESSMENT; GERMANY; HEALTH STATUS; HUMAN; INSOMNIA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS; WHOLE BODY RADIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GERMANY; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; STEM CELL TRANSPLANTATION; SURVIVORS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 84857509612     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.613132     Document Type: Article

References (37)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkins lymphomas: Clinical features of the major histologic subtypes. Non-Hodgki ' s Lymphoma Classifi cation Project. J. Clin. Oncol. 1998;16:2780-2795. (Pubitemid 28363044)
2. G roves FD, Linet MS, Travis LB., et al. Cancer surveillance series: non-Hodgkins lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J. Natl. Cancer Inst. 2000;92:1240-1251. (Pubitemid 30627732)
3. C hiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkins lymphoma. Clin Lymphoma 2003;4:161-168.
4. K ornacker M, Stumm J, Pott C., et al. Characteristics of relapse after autologous stem cell transplantation for follicular lymphoma: A longterm follow-up. Ann. Oncol. 2009;20:722-728.
5. R ohatiner AZ, Nadler L, Davies AJ., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J. Clin. Oncol. 2007;25:2554-2559. (Pubitemid 47044812)
6. M ontoto S, Canals C, Rohatiner AZ., et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry study. Leukemia 2007;21:2324-2331. (Pubitemid 350011705)
7. V ose JM, Bierman PJ, Loberiza FR., et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: Eff ect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008;14:36-42. (Pubitemid 350301030)
8. W itzens-Harig M, Dreger P. Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 2010;51:967-974.
9. P ettengell R, Donatti C, Hoskin P., et al. Th e impact of follicular lymphoma on health-related quality of life. Ann. Oncol. 2008;19:570-576. (Pubitemid 351325681)
10. S mith SK, Crespi CM, Petersen L., et al. Th e impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology 2010;19:1259-1267.
11. Smith SK, Zimmerman S, Williams CS., et al. Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 2009;115:3312-3323.
12. Czuczman M, Straus D, Gribben J., et al. Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leuk Lymphoma 2010.
13. Ruffer JU, Flechtner H, Tralls P., et al. Fatigue in longterm survivors of Hodgkins lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur. J. Cancer 2003;39: 2179-2186. (Pubitemid 37297743)
14. H jermstad MJ, Fossa SD, Oldervoll L., et al. Fatigue in long-term Hodgkins disease survivors: A follow-up study. J. Clin. Oncol. 2005;23: 6587-6595. (Pubitemid 46190252)
15. K onig HH, Bernert S, Angermeyer MC. [Health status of the German population: Results of a representative survey using the EuroQol questionnaire]. Gesundheitswesen 2005;67:173-182. (Pubitemid 40523398)
16. S chwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur. J. Cancer 2001;37:1345-1351. (Pubitemid 32588744)
17. F ox-Rushby J, Selai C. What concepts does the EQ-5D measure? Intentions and interpretations. In: Brooks R, Rabin R, de Charro F, editors. Th e measurement and valuation of health status using EQ-5D: A European perspective: Evidence from the EuroQol BIO MED Research Programme. Rotterdam: Kluwer Academic Publishers; 2003. pp 167 - 168.
18. Fayers P, Bottomley A. Quality of life research within the EORTC- the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 2002;38(Suppl. 4):S125-S133. (Pubitemid 34169774)
19. A aronson NK, Ahmedzai S, Bergman B., et al. Th e European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
20. Fayers P, Aaronson N, Bjordal K., et al.; on behalf of the EORTC Quality of Life Group. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC; 2001.
21. Kornacker M, Stumm J, Pott C., et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: A long-term follow-up. Ann. Oncol. 2009;20:722-728.
22. F rick E, Borasio GD, Zehentner H., et al. Individual quality of life of patients undergoing autologous peripheral blood stem cell transplantation. Psychooncology 2004;13:116-124. (Pubitemid 38247768)
23. H acker ED, Ferrans CE. Quality of life immediately after peripheral blood stem cell transplantation. Cancer Nurs 2003;26:312-322. (Pubitemid 36903886)
24. W ettergren L, Sprangers M, Bjorkholm M., et al. Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument. Psychooncology 2008; 17:338-346. (Pubitemid 351513682)
25. J o JC, Kang BW, Jang G., et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkins lymphoma patients: Comparative analysis of effi cacy and toxicity. Ann.Hematol 2008;87:43-48. (Pubitemid 350182540)
26. Puig N, de la Rubia J, Remigia MJ., et al. Morbidity and transplantrelated mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006;47:1488-1494. (Pubitemid 44364012)
27. C hap L, Shpiner R, Levine M., et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer: A non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997;20: 1063-1067. (Pubitemid 28043418)
28. Johnston LJ, Stockerl-Goldstein KE, Hu WW., et al. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkins lymphoma. Biol.Blood Marrow Transplant 2000;6:555-562.
29. Conner-Spady BL, Cumming C, Nabholtz JM., et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005;36:251-259. (Pubitemid 41136298)
30. Peppercorn J, Herndon J, Kornblith AB., et al. Quality of life among patients with stage II and III breast carcinoma random ized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: Results from Cancer and Leukemia Group B 9066. Cancer 2005;104: 1580-1589. (Pubitemid 41437420)
31. Gulbrandsen N, Wisloff F, Brinch L., et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med. Oncol. 2001;18:65-77. (Pubitemid 32906738)
32. C arlson LE, Koski T, Gluck S. Longitudinal eff ects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer. Bone Marrow Transplant 2001;27:989-998. (Pubitemid 32529882)
33. H ensel M, Egerer G, Schneeweiss A., et al. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann. Oncol. 2002;13:209-217. (Pubitemid 34704971)
34. Wettergren L, Bjorkholm M, Axdorph U., et al. Determinants of health-related quality of life in long-term survivors of Hodgkins lymphoma. Qual Life Res 2004;13:1369-1379. (Pubitemid 39221624)
35. H jermstad MJ, Oldervoll L, Fossa SD., et al. Quality of life in longterm Hodgkins disease survivors with chronic fatigue. Eur. J. Cancer 2006;42:327-333. (Pubitemid 43132887)
36. Greil R, Holzner B, Kemmler G., et al. Retrospective assessment of quality of life and treatment outcome in patients with Hodgkins disease from 1969 to 1994. Eur. J. Cancer 1999;35:698-706. (Pubitemid 29258136)
37. Norum J, Wist EA. Quality of life in survivors of Hodgkins disease. Qual Life Res 1996;5:367-374. (Pubitemid 26230067)